CyFlow CD34 Purified
品番 | BL106959 | ||
---|---|---|---|
抗体名 | Anti-Hu CD34 PURI,4H11[APG] | ||
包装単位 | 0.1 mg | ||
濃度 | 1 mg/ml | ||
容量 | 0.1 ml | ||
関連製品 (アイソタイプコントロール) |
Mouse IgG1 Purified (BJ561896) Mouse IgG1 Purified (AS224818) |
||
反応性|交差吸着 | Human | レーザー | |
抗原 | CD34 | 最大蛍光波長 | - |
クローン | 4H11[APG] | 最大励起波長 | - |
ホスト | Mouse | 標識/Format | Purified |
アイソタイプ | IgG1 | 研究分野 | Immunophenotyping |
クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Hu CD34 PURI,4H11[APG]
特異性
The mouse monoclonal antibody 4H11[APG] recognizes Class III epitope on CD34 antigen, a 110-115 kDa monomeric transmembrane phosphoglycoprotein expressed on hematopoietic progenitors cells and on the most pluripotential stem cells; it is gradually lost on progenitor cells. The antibody 4H11[APG] completely blocks binding of Class II antibody QBEnd10 and Class III antibodies BIRMA K3 and 8G12 on KG1a cell line.
抗原情報
CD34 (Mucosialin) is a highly glycosylated monomeric 111-115 kDa surface protein, which is present on many stem cell populations. It is a well established stem cell marker, though its expression on human hematopoietic stem cells is reversible. CD34 probably serves as a surface receptor that undergoes receptor-mediated endocytosis and regulates adhesion, differentiation and proliferation of hematopoietic stem cells and other progenitors. CD34 expression is likely to represent a specific state of hematopoietic development that may have altered adhering properties with expanding and differentiating capabilities in both in vitro and in vivo conditions.
利用方法
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Dao MA, Arevalo J, Nolta JA: Reversibility of CD34 expression on human hematopoietic stem cells that retain the capacity for secondary reconstitution. Blood. 2003·Jan·1; 101(1):112‑8. <·PMID:·12589631·>
• Elknerová K, Lacinová Z, Soucek J, Marinov I, Stöckbauer P: Growth inhibitory effect of the antibody to hematopoietic stem cell antigen CD34 in leukemic cell lines. Neoplasma. 2007; 54(4):311‑20. <·PMID:·17822321·>
• Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, Gulati S, Luthra PM: Three‑dimensional structure prediction of the interaction of CD34 with the SH3 domain of Crk‑L. Stem·Cells·Dev. 2005·Oct; 14(5):470‑7. <·PMID:·16305332·>
• Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, Luthra PM: Hematopoietic stem cell antigen CD34: role in adhesion or homing. Stem·Cells·Dev. 2006·Jun; 15(3):305‑13. <·PMID:·16846369·>
• Kish DD, Gorbachev AV, Fairchild RL: CD8+ T cells produce IL‑2, which is required for CD(4+)CD25+ T cell regulation of effector CD8+ T cell development for contact hypersensitivity responses. J·Leukoc·Biol. 2005·Sep; 78(3):725‑35. <·PMID:·16000396·>
• Krauter J, Hartl M, Hambach L, Kohlenberg A, Gunsilius E, Ganser A, Heil G: Receptor‑mediated endocytosis of CD34 on hematopoietic cells after stimulation with the monoclonal antibody anti‑HPCA‑1. J·Hematother·Stem·Cell·Res. 2001·Dec; 10(6):863‑71. <·PMID:·11798512·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN